Trials / Unknown
UnknownNCT05121363
A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma
A Single-arm, Multicenter Phase II Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 113 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A clinical trial to evaluate TQB2858 injection combined with Anlotinib Hydrochloride capsule in the treatment of recurrent or metastatic advanced endometrial carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2858 injection | TQB2858 is an anti-programmed death receptor 1(anti-PD-1) /Transforming growth factor-β(TGF-β )bi-functional fusion protein |
| DRUG | Anlotinib Hydrochloride capsules | Anlotinib Hydrochloride is a multi-target tyrosine kinase inhibitor. |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2023-05-01
- Completion
- 2023-07-01
- First posted
- 2021-11-16
- Last updated
- 2021-11-30
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05121363. Inclusion in this directory is not an endorsement.